Changes in tumor markers, liver function of patients with hepatic carcinoma in treatment with sorafenib and TACE
ZHAO Xiaohua
WEN Zhenping
SUN Yushu
WEI Yefeng
Abstract：Objective To observe the effect of sorafenib combined with transcatheter arterial chemoembolization ( TACE) treatment in patients with hepatocellular carcinoma and changes of tumor markers and liver function .Methods Six-ty-eight cases of patients with middle and late hepatic carcinoma were selected , which were treated in hospital from February 2013 to October 2015, and they were divided into the observation group (34 cases) and control group (34 cases).The pa-tients of control group were treated with percutaneous transcatheter arterial chemoembolization ( TACE) .On the basis of con-trol group, the patients of observation group were treated with sorafenib .Observe and compare the clinic results , adverse reac-tions and changes of the levels of tumor markers and liver function of the two groups .Results After the appropriate treatment , the patients of the observation group got objective response rate and clinical benefit rate of 50.0% and 79.4%, which were significantly better than the 26.5%and 55.9%of the control group (χ2 =3.985,χ2 =4.300, P =0.046, P =0.038);In the terms of AFP, CEA, CA125 and CA19-9, the patients of two groups were all significantly decreased than before ( t =54 .277 , t =12 .578 , t =27 .704 , t =26 .410;t =45 .362 , t =7 .662 , t =17 .131 , t =19 .450 , P =0 .000 , P =0 .000 , P =0.000, P =0.000;P =0.000, P =0.000, P =0.000, P =0.000), and the patients of the observation group got more significant decline ( t =35.546, t =3.499, t =11.780, t =5.690, P =0.000, P =0.000, P =0.000, P =0.000); In the terms of ALT, TBil, the patients of two groups were all significantly improved than before ( t =11.071, t =6.114;t =0.730, t =4.293, P =0.000, P =0.000, P =0.000, P =0.000), but in the terms of ALB, There was no significant changes occurred of two groups ( t =1.612;t =0.932, P >0.05);The adverse reactions of observation group were less than the control group, but there was no statistically significant between the two groups (χ2 =0.534,χ2 =0.236,χ2 =0.060,χ2 =0 o.657,χ2 =1.643,χ2 =0.063, P =0.465, P =0.627, P =0.806, P =0.417, P =0.200, P =0.801).Conclusion Sorafenib combined with TACE in the treatment of patients with advanced hepatocellular carcinoma can achieve good thera -peutic effect and improve the liver function , which has positive clinical significance .
Keywords：Hepatic carcinomaSorafenibTranscatheter arterial chemoembolizationLiver function
Publication Date：2016-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 1246-1249 )